Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Subonderzoek 06C: Een onderzoek naar Sacituzumab Tirumotecan (MK-2870) met Pembrolizumab (MK-3475) en chemotherapie bij deelnemers met eerstelijns lokaal gevorderd inoperabel/gemetastaseerd gastro-oesofageaal adenocarcinoom (MK-3475-06C/KEYMAKER-U06)

12 november 2026 bijgewerkt door: Merck Sharp & Dohme LLC

Een fase 1/2 open-label, parapluplatformontwerpstudie van MK-2870 met Pembrolizumab (MK-3475) en chemotherapie bij deelnemers met 1 liter lokaal gevorderd, niet-reseceerbaar/metastatisch gastro-oesofageaal adenocarcinoom (maagadenocarcinoom, gastro-oesofageale junctieadenocarcinoom en slokdarmadenocarcinoom): Deelonderzoek 06C

This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma.

This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for investigational agents in combination with chemotherapy and immunotherapy. There is no formal hypothesis in this study.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

The master protocol is MK-3475-U06.

Studietype

Ingrijpend

Inschrijving (Geschat)

160

Fase

  • Fase 2
  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

  • Brazilië
      • São Paulo, Brazilië, 03102-006
        • Werving
        • IBCC - Instituto Brasileiro de Controle do Câncer ( Site 6304)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 551144500300
      • São Paulo, Brazilië, 01246-000
        • Werving
        • ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 6300)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 551138932000
    • Rio Grande do Norte
      • Natal, Rio Grande do Norte, Brazilië, 59062-000
        • Werving
        • Liga Norte Riograndense Contra o Câncer ( Site 6303)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: +558440095595
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brazilië, 91350-200
        • Werving
        • Hospital Nossa Senhora da Conceição ( Site 6301)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: +5551993590437
  • Chili
      • Antofagasta, Chili, 1263521
        • Werving
        • Bradford Hill Norte ( Site 6407)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 56442023631
    • Los Lagos Region
      • Port Montt, Los Lagos Region, Chili, 5500243
        • Werving
        • Clínica Puerto Montt ( Site 6409)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 56961687093
    • Maule Region
      • Talca, Maule Region, Chili, 3481349
        • Voltooid
        • Centro de Investigación del Maule ( Site 6408)
    • Region M. de Santiago
      • Santiago, Region M. de Santiago, Chili, 7500921
        • Werving
        • FALP-UIDO ( Site 6400)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 56224205098
      • Santiago, Region M. de Santiago, Chili, 7560908
        • Werving
        • Centro de Oncología de Precisión-Oncology ( Site 6404)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 56225189885
      • Santiago, Region M. de Santiago, Chili, 7620002
        • Werving
        • Clínica UC San Carlos de Apoquindo ( Site 6405)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 56934271024
      • Santiago, Region M. de Santiago, Chili, 8420383
        • Werving
        • Bradfordhill-Clinical Area ( Site 6401)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 56229490970
  • China
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100142
        • Werving
        • Beijing Cancer hospital-Digestive Oncology ( Site 5500)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: (010)88196317
    • Fujian
      • Fuzhou, Fujian, China, 350025
        • Werving
        • The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army ( Site 5501)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 0591-22859606
      • Xiamen, Fujian, China, 361003
        • Werving
        • The First Affiliated hospital of Xiamen University ( Site 5503)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 0592-2139767
    • Henan
      • Zhengzhou, Henan, China, 450008
        • Werving
        • Henan Cancer Hospital ( Site 5504)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 400-0371-818
    • Jiangxi
      • Nanchang, Jiangxi, China, 330000
        • Werving
        • The First Affiliated Hospital of Nanchang University ( Site 5514)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 0791-86427234
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200032
        • Actief, niet wervend
        • Fudan University Shanghai Cancer Center ( Site 5513)
    • Xinjiang
      • Ürümqi, Xinjiang, China, 841100
        • Actief, niet wervend
        • Xinjiang Medical University Cancer Hospital - Urumqi ( Site 5506)
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310016
        • Werving
        • Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 5510)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 0571 8609 0073
  • Duitsland
    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, Duitsland, 69120
        • Werving
        • NCT-Department of Medical Oncology ( Site 6809)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: +49 62215637784
    • Free and Hanseatic City of Hamburg
      • Erdgeschoss, Free and Hanseatic City of Hamburg, Duitsland, 22297
        • Werving
        • HOPE Hamburg/Norddeutsches Studienzentrum fuer Innovative Onkologie ( Site 6807)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: + 4940360352246
    • North Rhine-Westphalia
      • Düsseldorf, North Rhine-Westphalia, Duitsland, 40225
        • Voltooid
        • Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 6802)
  • Frankrijk
    • Finistere
      • Brest, Finistere, Frankrijk, 29200
        • Werving
        • CHU-BREST Cavale Blanche ( Site 5104)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 33298223428
    • Nord
      • Lille, Nord, Frankrijk, 59037
        • Werving
        • CIC. ( Site 5100)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: +33320445461
    • Île-de-France Region
      • Paris, Île-de-France Region, Frankrijk, 75013
        • Werving
        • Pitie Salpetriere University Hospital-Hepato-Gastro-Enterology ( Site 5102)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: +331 42 16 10 41
  • Italië
      • Milan, Italië, 20132
        • Werving
        • Ospedale San Raffaele-Oncologia Medica ( Site 5202)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: +390226437615
    • Emilia-Romagna
      • Meldola, Emilia-Romagna, Italië, 47014
        • Werving
        • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 5207)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 0543739100
    • Lombardy
      • Milan, Lombardy, Italië, 20133
        • Werving
        • Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 5200)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 0223903807
    • Tuscany
      • Pisa, Tuscany, Italië, 56126
        • Werving
        • Azienda Ospedaliero Universitaria Pisana ( Site 5206)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 050992454
  • Noorwegen
      • Oslo, Noorwegen, 0379
        • Werving
        • Oslo universitetssykehus, Radiumhospitalet ( Site 6501)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 4723026600
  • Taiwan
      • Taichung, Taiwan, 404
        • Werving
        • China Medical University Hospital ( Site 6007)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 886422052121x15057
      • Tainan, Taiwan, 704
        • Werving
        • National Cheng Kung University Hospital ( Site 6001)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: +88662353535x4559
      • Taipei, Taiwan, 10048
        • Werving
        • National Taiwan University Hospital-Oncology ( Site 6000)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: +88623123456x267852
      • Taipei, Taiwan, 112
        • Werving
        • Taipei Veterans General Hospital ( Site 6005)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: +88628717270x131
  • Thailand
    • Bangkok
      • Bangkoknoi, Bangkok, Thailand, 10700
        • Werving
        • Faculty of Medicine Siriraj Hospital ( Site 6102)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: +6624194489
      • Pathumwan, Bangkok, Thailand, 10330
        • Werving
        • Chulalongkorn Hospital ( Site 6104)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 022564533
      • Ratchathewi, Bangkok, Thailand, 10400
        • Werving
        • Ramathibodi Hospital ( Site 6103)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 022011671
    • Changwat Songkhla
      • Hat Yai, Changwat Songkhla, Thailand, 90110
        • Werving
        • Songklanagarind hospital ( Site 6101)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: +6674451469
  • Verenigde Staten
    • Arizona
      • Tucson, Arizona, Verenigde Staten, 85719
        • Werving
        • University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 520-621-2449
    • California
      • Los Angeles, California, Verenigde Staten, 90404
        • Werving
        • UCLA Hematology/Oncology - Santa Monica ( Site 6905)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 310-570-1453
    • Kentucky
      • Louisville, Kentucky, Verenigde Staten, 40202
        • Voltooid
        • Norton Hospital-Norton Cancer Institute - Downtown ( Site 6900)
    • Michigan
      • Grand Rapids, Michigan, Verenigde Staten, 49503
        • Werving
        • The Cancer and Hematology Centers ( Site 6912)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 616-975-3065
    • New York
      • East Syracuse, New York, Verenigde Staten, 13057
        • Werving
        • Hematology-Oncology Associates of Central NY, P.C. ( Site 6925)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 315-472-7504
      • New York, New York, Verenigde Staten, 10032
        • Voltooid
        • Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 6907)
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15232
        • Werving
        • UPMC Hillman Cancer Center-UPMC ( Site 6904)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 816-898-9413
    • Texas
      • Houston, Texas, Verenigde Staten, 77030
        • Werving
        • University of Texas MD Anderson Cancer Center ( Site 6920)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 833-589-0868
  • Zuid -Korea
      • Seoul, Zuid -Korea, 05505
        • Werving
        • Asan Medical Center-Department of Oncology ( Site 5901)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: +82230103217
      • Seoul, Zuid -Korea, 06351
        • Werving
        • Samsung Medical Center-Division of Hematology/Oncology ( Site 5900)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: 82234101795
  • Zwitserland
    • Canton of Geneva
      • Geneva, Canton of Geneva, Zwitserland, 1211
        • Werving
        • Hôpitaux Universitaires de Genève (HUG) ( Site 6701)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: +41 22 372 29 01
    • Kanton Graubünden
      • Chur, Kanton Graubünden, Zwitserland, 7000
        • Werving
        • Kantonsspital Graubünden-Medizin ( Site 6700)
        • Contact:
          • Study Coordinator
          • Telefoonnummer: +41 81 256 61 11

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Has histologically and/or cytologically confirmed diagnosis of previously untreated locally advanced unresectable or metastatic first-line (1L) gastroesophageal adenocarcinoma
  • Is not expected to require tumor resection during the treatment course
  • Tumor tissue must be confirmed as negative for human epidermal growth factor receptor 2 (HER2) expression as classified by American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines
  • Core/excisional biopsy of a tumor lesion not previously irradiated has been provided
  • Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline
  • Participants with endocrine-related AEs who are adequately treated with hormone replacement therapy are eligible
  • Has adequate organ function
  • Has measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as determined by the local site investigator/radiology assessment and verified by blinded independent central review (BICR)
  • Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 3 days prior to the first dose of study intervention
  • Has a life expectancy of at least 6 months
  • Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to allocation/randomization
  • Participants with history of Hepatitis C Virus (HCV) infection are eligible if HCV viral load is undetectable at screening
  • Human Immunodeficiency Virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has squamous cell or undifferentiated gastroesophageal cancer.
  • Has had previous therapy for locally advanced unresectable or metastatic gastric/gastroesophageal junction (GEJ)/esophageal adenocarcinoma
  • Has experienced weight loss >20% over 3 months before the first dose of study intervention
  • Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
  • Has Grade ≥2 peripheral neuropathy
  • Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
  • Has uncontrolled, significant cardiovascular disease or cerebrovascular disease within 6 months preceding study intervention
  • Has accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to enrollment
  • Has history of human immunodeficiency virus (HIV) infection with Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Has received prior treatment with a trophoblast antigen 2 (TROP2)-targeted or anti-human epidermal growth factor receptor 3 (HER3) targeted agents
  • Has received prior treatment with a topoisomerase I inhibitor-based antibody-drug conjugate (ADC) and/or a topoisomerase I inhibitor-based chemotherapy
  • Has received prior systemic anticancer therapy within 4 weeks before the first dose of study intervention
  • Has received prior therapy with an anti-Programmed Cell Death Protein 1 (PD-1), anti-Programmed Cell Death-Ligand 1 (PD-L1), anti-Programmed Cell Death-Ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (TCR)
  • Has received prior radiotherapy within 2 weeks of start of study intervention, or has radiation related toxicities, requiring corticosteroids
  • Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
  • Has received a strong inducer/inhibitor of CYP3A4 that cannot be discontinued
  • Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration
  • Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
  • Has known additional malignancy that is progressing or has required active treatment within the past 3 years
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Has Severe hypersensitivity (≥Grade 3) to pembrolizumab, sacituzumab tirumotecan, patritumab deruxtecan, or other biologic therapy, chemotherapy (ie, oxaliplatin, fluorouracil, capecitabine), leucovorin, levoleucovorin, or any of their excipients
  • Has active autoimmune disease that has required systemic treatment in the past 2 years
  • Has history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, or current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at Screening
  • Has an active infection requiring systemic therapy
  • Has concurrent active hepatitis B (defined as Hepatitis B surface antigen [HBsAg] positive and/or detectable HBV DNA) and hepatitis C virus (defined as anti-hepatitis C virus [HCV] Ab positive and detectable HCV ribonucleic acid [RNA] infection or a known history of hepatitis B and/or C infection
  • Has history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's ability to cooperate with the requirements of the study
  • Has gastrointestinal (GI) obstruction, poor oral intake, or difficulty in taking oral medication
  • Has poorly controlled diarrhea
  • Has had a major surgery or significant traumatic injury within 4 weeks before the first dose of study intervention
  • Has history of allogeneic tissue/solid organ transplant
  • Has not adequately recovered from major surgery or has ongoing surgical complications

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: Pembrolizumab plus Chemotherapy

Participants will receive pembrolizumab 400 mg via intravenous (IV) injection on day 1 of every 6 week cycle (Q6W) for up to 18 cycles (up to ~2 years) AND investigator's choice of CAPOX chemotherapy (capecitabine 1000 mg/m^2 orally twice daily for 14 days every 3 weeks (Q3W) and oxaliplatin 130 mg/m^2 via IV infusion Q3W) OR mFOLFOX6 chemotherapy (oxaliplatin 85 mg/m^2 via IV infusion Q3W; 5-Fluorouracil (5-FU) 400 mg/^2 via bolus IV plus 2400 mg/m^2 continuous IV once every 2 weeks (Q2W); and leucovorin 400 mg/m^2 via IV infusion Q2W OR levoleucovorin 200 mg/m^2 Q2W).
Biologisch: Pembrolizumab

Administered via intravenous (IV) infusion.

Andere namen:
  • MK-3475
  • Keytruda®
Geneesmiddel: Capecitabine

Administered via oral tablet.

Andere namen:
  • XELODA
Geneesmiddel: Leucovorin

Administered via IV infusion.

Andere namen:
  • folinezuur
  • WELLCOVORIN®
  • calciumfolinaat
Geneesmiddel: Levoleucovorin

Administered via IV infusion.

Andere namen:
  • FUSILEV®
  • calciumlevofolinaat
  • levofolinezuur
Geneesmiddel: 5-Fluorouracil (5-FU)

Administered via IV infusion

Andere namen:
  • ADRUCIL®
Geneesmiddel: Oxaliplatin

Administered via IV infusion
Experimenteel: Pembrolizumab plus Sacituzumab Tirumotecan plus Chemotherapy

Participants will receive sacituzumab tirumotecan via IV infusion on Days 1, 15, and 29 Q6W until discontinuation, pembrolizumab 400 mg via IV injection on day 1 Q6W for up to 18 cycles (up to ~2 years) AND investigator's choice of capecitabine 1000 mg/m^2 orally twice daily for 14 days Q3W OR 5-FU 2400 mg/m^2 IV once Q2W AND leucovorin 400 mg/m^2 via IV infusion Q2W OR levoleucovorin 200 mg/m^2 Q2W.
Biologisch: Pembrolizumab

Administered via intravenous (IV) infusion.

Andere namen:
  • MK-3475
  • Keytruda®
Geneesmiddel: Capecitabine

Administered via oral tablet.

Andere namen:
  • XELODA
Geneesmiddel: Leucovorin

Administered via IV infusion.

Andere namen:
  • folinezuur
  • WELLCOVORIN®
  • calciumfolinaat
Geneesmiddel: Levoleucovorin

Administered via IV infusion.

Andere namen:
  • FUSILEV®
  • calciumlevofolinaat
  • levofolinezuur
Geneesmiddel: 5-Fluorouracil (5-FU)

Administered via IV infusion

Andere namen:
  • ADRUCIL®
Biologisch: Sacituzumab Tirumotecan (sac-TMT)

Administered via IV infusion.

Andere namen:
  • SKB264
  • MK-2870
Experimenteel: Pembrolizumab plus Patritumab Deruxtecan plus Chemotherapy

Participants will receive patritumab deruxtecan via IV infusion on Days 1 and 22 Q6W until discontinuation, pembrolizumab 400 mg via IV injection on day 1 Q6W for up to 18 cycles (up to ~2 years) AND investigator's choice of capecitabine 1000 mg/m^2 orally twice daily for 14 days Q3W OR 5-FU 2400 mg/m^2 IV once Q2W AND leucovorin 400 mg/m^2 via IV infusion Q2W OR levoleucovorin 200 mg/m^2 Q2W.
Biologisch: Pembrolizumab

Administered via intravenous (IV) infusion.

Andere namen:
  • MK-3475
  • Keytruda®
Geneesmiddel: Capecitabine

Administered via oral tablet.

Andere namen:
  • XELODA
Geneesmiddel: Leucovorin

Administered via IV infusion.

Andere namen:
  • folinezuur
  • WELLCOVORIN®
  • calciumfolinaat
Geneesmiddel: Levoleucovorin

Administered via IV infusion.

Andere namen:
  • FUSILEV®
  • calciumlevofolinaat
  • levofolinezuur
Geneesmiddel: 5-Fluorouracil (5-FU)

Administered via IV infusion

Andere namen:
  • ADRUCIL®
Biologisch: Patritumab Deruxtecan

Administered via IV infusion

Andere namen:
  • U3-1402
  • HER3-DXd
  • MK-1022

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Safety Lead-in Phase: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)
Tijdsspanne: Up to approximately 28 days

DLTs are defined as any treatment-emergent adverse events (TEAEs) not attributable to disease or disease-related processes that occur during the DLT evaluation period and are a Grade 3 or higher according to the National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) Version 5.0. The percentage of participants who experience at least one DLT will be reported.
Up to approximately 28 days
Safety Lead-in Phase: Number of Participants Who Experienced an Adverse Event (AE)
Tijdsspanne: Up to approximately 28 days

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Up to approximately 28 days
Safety Lead-in Phase: Number of Participants Who Discontinued Study Intervention Due to an AE
Tijdsspanne: Up to approximately 28 days

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Up to approximately 28 days
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Tijdsspanne: Up to approximately 28 months

ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience CR or PR as assessed by BICR will be presented.
Up to approximately 28 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Progression-Free Survival (PFS) per RECIST 1.1 as Assessed by BICR
Tijdsspanne: Up to approximately 55 months

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death from any cause, whichever occurs first. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.
Up to approximately 55 months
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR
Tijdsspanne: Up to approximately 55 months

For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until PD or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented.
Up to approximately 55 months
Overall Survival (OS)
Tijdsspanne: Up to approximately 55 months

OS is defined as the time from randomization to the date of death from any cause.
Up to approximately 55 months
Number of Participants Who Experience an Adverse Event (AE)
Tijdsspanne: Up to approximately 55 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Up to approximately 55 months
Number of Participants Who Discontinue Study Treatment Due to an AE
Tijdsspanne: Up to approximately 55 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Up to approximately 55 months
Incidence of Antidrug Antibodies (ADA) to investigational agents - (sacituzumab tirumotecan (sac-TMT, MK-2870) and patritumab deruxtecan (HER3-DXd))
Tijdsspanne: At designated timepoints up to approximately 55 months

Blood samples collected at designated timepoints will be used to determine the ADA response to investigational agents. The incidence of ADAs over time will be presented.
At designated timepoints up to approximately 55 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Merck Sharp & Dohme LLC

Onderzoekers

  • Studie directeur: Medical Director, Merck Sharp & Dohme LLC

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Nuttige links

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

20 september 2024

Primaire voltooiing (Geschat)

12 september 2029

Studie voltooiing (Geschat)

12 september 2029

Studieregistratiedata

Eerst ingediend

17 juni 2024

Eerst ingediend dat voldeed aan de QC-criteria

17 juni 2024

Eerst geplaatst (Werkelijk)

24 juni 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

13 november 2026

Laatste update ingediend die voldeed aan QC-criteria

12 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • 3475-06C
  • MK-3475-06C (Andere identificatie: MSD)
  • KEYMAKER-06C (Andere identificatie: MSD)
  • U1111-1299-8084 (Register-ID: UTN)
  • 2023-509307-33-00 (Register-ID: EU CT)
  • 2023 (Subsidie/contract van de Amerikaanse NIH)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren